
GlyTherix Peer Reviewed Publications

2023

Saikat Ghosh, Nicholas L. Fletcher, Pie Huda, Zachary H. Houston, Christopher B. Howard, Maria E. Lund, Yanling Lu, Douglas H. Campbell, Bradley J. Walsh, and Kristofer J. Thurecht, 'Pharmacokinetics and Biodistribution of 89Zr-Miltuximab and Its Antibody Fragments as Glypican-1 Targeting Immuno-PET Agents in Glioblastoma', *Mol. Pharmaceutics* 2023. <https://doi.org/10.1021/acs.molpharmaceut.2c00760>

2022

Ghosh, S, Huda, P, Fletcher, NL, Howard, CB, Walsh, B, Campbell, D, Pinkham, MB & Thurecht, KJ 2022, 'Antibody-based formats to target glioblastoma: overcoming barriers to protein drug delivery', *Molecular Pharmaceutics*, vol. 19, no. 5, pp. 1233-1247. <https://doi.org/10.1021/acs.molpharmaceut.1c00996>

Ghosh, S, Huda, P, Fletcher, N, Campbell, D, Thurecht, K & Walsh, BJ 2022, 'Clinical development of an anti-GPC-1 antibody for the treatment of cancer', *Expert Opinion on Biological Therapy*. <https://doi.org/10.1080/14712598.2022.2033204>

2021

Polikarpov, DM, Campbell, DH, Zaslavsky, AB, Lund, ME, Wu, A, Lu, Y, Palapattu, GS, Walsh, BJ, Zvyagin, AV & Gillatt, DA 2021, 'Glypican-1 as a target for fluorescence molecular imaging of bladder cancer', *International Journal of Urology*. <https://doi.org/10.1111/iju.14683>

Sabanathan, D, Lund, ME, Campbell, D, Walsh, B & Gurney, H 2021, 'Radioimmunotherapy for solid tumors: spotlight on glypican-1 as a radioimmunotherapy target', *Therapeutic Advances in Medical Oncology*, vol. 13, pp. 1-21. <https://doi.org/10.1177/17588359211022918>

Bailey, DL, Sabanathan, D, Aslani, A, Campbell, DH, Walsh, BJ & Lengkeek, NA 2021, 'RetroSPECT: Gallium-67 as a long-lived imaging agent for theranostics', *Asia Oceania Journal of Nuclear Medicine and Biology*, vol. 9, no. 1, pp. 1-8. <https://doi.org/10.22038/AOJNMB.2020.51714.1355>

Sabanathan, D, Campbell, DH, Velonas, VM, Wissmueller, S, Mazure, H, Trifunovic, M, Poursoltan, P, Shon, KH, Mackay, TR, Lund, ME, Lu, Y, Roach, PJ, Bailey, DL, Walsh, BJ, Gillatt, D & Gurney, H 2021, 'Safety and tolerability of Miltuximab®: a first in human study in patients with advanced solid cancers', *Asia Oceania Journal of Nuclear Medicine and Biology*, vol. 9, no. 2, pp. 86-100. <https://doi.org/10.22038/AOJNMB.2021.55600.138>

2020

Lund, ME, Howard, CB, Thurecht, KJ, Campbell, DH, Mahler, SM & Walsh, BJ 2020, 'A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells', *BMC Cancer*, vol. 20, 1214, pp. 1-13. <https://doi.org/10.1186/s12885-020-07562-1>

Polikarpov, DM, Campbell, DH, Lund, ME, Lu, Y, Lu, Y, Wu, J, Walsh, BJ, Zvyagin, AV & Gillatt, DA 2020, 'The feasibility of Miltuximab®-IRDye700DX-mediated photoimmunotherapy of solid tumors', *Photodiagnosis and Photodynamic Therapy*, vol. 32, 102064, pp. 1-9. <https://doi.org/10.1016/j.pdpdt.2020.102064>

Yeh, MC, Tse, BWC, Fletcher, NL, Houston, ZH, Lund, M, Volpert, M, Stewart, C, Sokolowski, KA, Jeet, V, Thurecht, KJ, Campbell, DH, Walsh, BJ, Nelson, CC & Russell, PJ 2020, 'Targeted beta therapy of prostate cancer with ¹⁷⁷Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)', *EJNMMI Research*, vol. 10, 46. <https://doi.org/10.1186/s13550-020-00637-x>

Polikarpov, D, Campbell, DH, McRobb, L, Wu, J, Lund, ME, Lu, Y, Deyev, SM, Davidson, AS, Walsh, BJ, Zvyagin, A & Gillatt, D 2020, 'Near-infrared molecular imaging of glioblastoma by Miltuximab®-IRDye800CW as a potential tool for fluorescence-guided surgery', *Cancers*, vol. 12, no. 4, 984, pp. 1-14. <https://doi.org/10.3390/cancers12040984>

Lund, ME, Campbell, DH & Walsh, BJ 2020, The role of Glypican-1 in the tumour microenvironment. in A Birbrair (ed.), *Tumor Microenvironment: Extracellular Matrix Components – Part A*. Advances in Experimental Medicine and Biology, vol. 1245, Springer, Springer Nature, Cham, Switzerland, pp. 163-176. https://doi.org/10.1007/978-3-030-40146-7_8

2019

Polikarpov, D, Liang, L, Care, A, Sunna, A, Campbell, D, Walsh, B, Balalaeva, I, Zvyagin, A, Gillatt, D & Guryev, E 2019, 'Functionalized upconversion nanoparticles for targeted labelling of bladder cancer cells', *Biomolecules*, vol. 9, no. 12, 820, pp. 1-11. <https://doi.org/10.3390/biom9120820>

2018

Levin, RA, Lund, ME, Truong, Q, Wu, A, Shore, ND, Saltzstein, DR, Concepcion, RS, Paivanas, TA, Breda, AV, Beebe-Dimmer, J, Ruterbusch, JJ, Wissmueller, S, Campbell, DH & Walsh, BJ 2018, 'Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker', *Oncotarget*, vol. 9, no. 32, pp. 22359-22367. <https://doi.org/10.18632/oncotarget.25009>

Campbell, DH, Lund, ME, Nocon, AL, Cozzi, PJ, Frydenberg, M, De Souza, P, Schiller, B, Beebe-Dimmer, JL, Ruterbusch, JJ & Walsh, BJ 2018, 'Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer', *PLoS ONE*, vol. 13, no. 4, e0196017. <https://doi.org/10.1371/journal.pone.0196017>

2016

Truong, Q, Justiniano, IO, Nocon, AL, Soon, JT, Wissmueller, S, Campbell, DH & Walsh, BJ 2016, 'Glypican-1 as a biomarker for prostate cancer: Isolation and characterization', *Journal of Cancer*, vol. 7, no. 8, pp. 1002-1009. <https://doi.org/10.7150/jca.14645>